The University of Southampton
University of Southampton Institutional Repository

Developing a 3-dimensional multicellular bone model of osteosarcoma

Developing a 3-dimensional multicellular bone model of osteosarcoma
Developing a 3-dimensional multicellular bone model of osteosarcoma
The main treatment for osteosarcoma patients remains a combination of surgery followed by neoadjuvant chemotherapy. The drug Mifamurtide, introduced in 2001, is routinely given concurrently with chemotherapy in the UK, and works by activating macrophages in an inflammatory manner. Unfortunately, there are mixed reviews on the therapeutic benefit of Mifamurtide, and few new drugs and therapies show efficacy in osteosarcoma clinical trials. Greater understanding of the osteosarcoma microenvironment, and the cellular interactions involved in tumour proliferation, could introduce novel targets for future therapies. To explore this a 3D multicellular model of osteosarcoma was developed, replicating some of the cellular interactions of stromal and immune cells in a human bone structure.
A range of stromal, myeloid and osteosarcoma cells were initially characterised in 2D assays for inclusion in the 3D bone model. These included; human bone marrow stromal cells (HBMSCs), macrophages derived from bone marrow and peripheral blood mononuclear cells (PBMCs), as well as two osteosarcoma cell lines, Saos-2 and MG63. The human bone structure of the 3D bone models were made from the femoral head of patients undergoing hip replacement surgery, and were cultured either in conditioned media for 20 days or incubated on the chorioallantoic membrane (CAM) of fertilised chicken eggs. Micro-computed tomography (μCT) and histological techniques were used to validate the 3D bone models; to determine whether bone remodelling occurred, as well as characterising the migration and biological activity of the inserted cells.
Characterisation of the two osteosarcoma cell lines showed distinct differences in tri-lineage differentiation, with Saos-2 cells promoting an osteogenic phenotype and consequently being used in the 3D bone models. Skeletal location also proved to be important in the tri-lineage characterisation of the HBMSCs, with cells isolated from the femoral diaphysis (FD) and femoral epiphysis (FE) demonstrating distinct phenotypes. HBMSCs from the FD were used in the development of the 3D bone models due to the higher osteogenic potential, which is also found in osteosarcoma patients. The third cell type included in the 3D model were monocyte-derived macrophages (MDMs) differentiated from PBMCs, which showed a similar phenotype to human bone marrow-derived macrophages, but could be produced in greater quantities. The Saos-2 cells,
FD HBMSCs and MDMs were introduced into the 3D bone models. Changes in the expression of CD68, CD105 and RANK were found between combinations of the three cell types, as well as those treated with and without Mifamurtide. No significant changes in bone formation or resorption were detected.
In summary, a 3D multicellular bone model of osteosarcoma has been developed that holds the potential to be used to test new drugs and therapies. While further analysis is needed to determine whether the stromal and immune cell interactions replicate those found in the osteosarcoma microenvironment, it has been shown that multiple cell types can be combined in a 3D human bone scaffold, cultured on the CAM and remain viable.
University of Southampton
Smith, Hannah Louise
5f75b278-0dd4-4039-9f6f-75a96ad94035
Smith, Hannah Louise
5f75b278-0dd4-4039-9f6f-75a96ad94035
Beers, Stephen
a02548be-3ffd-41ab-9db8-d6e8c3b499a2

Smith, Hannah Louise (2022) Developing a 3-dimensional multicellular bone model of osteosarcoma. University of Southampton, Doctoral Thesis, 253pp.

Record type: Thesis (Doctoral)

Abstract

The main treatment for osteosarcoma patients remains a combination of surgery followed by neoadjuvant chemotherapy. The drug Mifamurtide, introduced in 2001, is routinely given concurrently with chemotherapy in the UK, and works by activating macrophages in an inflammatory manner. Unfortunately, there are mixed reviews on the therapeutic benefit of Mifamurtide, and few new drugs and therapies show efficacy in osteosarcoma clinical trials. Greater understanding of the osteosarcoma microenvironment, and the cellular interactions involved in tumour proliferation, could introduce novel targets for future therapies. To explore this a 3D multicellular model of osteosarcoma was developed, replicating some of the cellular interactions of stromal and immune cells in a human bone structure.
A range of stromal, myeloid and osteosarcoma cells were initially characterised in 2D assays for inclusion in the 3D bone model. These included; human bone marrow stromal cells (HBMSCs), macrophages derived from bone marrow and peripheral blood mononuclear cells (PBMCs), as well as two osteosarcoma cell lines, Saos-2 and MG63. The human bone structure of the 3D bone models were made from the femoral head of patients undergoing hip replacement surgery, and were cultured either in conditioned media for 20 days or incubated on the chorioallantoic membrane (CAM) of fertilised chicken eggs. Micro-computed tomography (μCT) and histological techniques were used to validate the 3D bone models; to determine whether bone remodelling occurred, as well as characterising the migration and biological activity of the inserted cells.
Characterisation of the two osteosarcoma cell lines showed distinct differences in tri-lineage differentiation, with Saos-2 cells promoting an osteogenic phenotype and consequently being used in the 3D bone models. Skeletal location also proved to be important in the tri-lineage characterisation of the HBMSCs, with cells isolated from the femoral diaphysis (FD) and femoral epiphysis (FE) demonstrating distinct phenotypes. HBMSCs from the FD were used in the development of the 3D bone models due to the higher osteogenic potential, which is also found in osteosarcoma patients. The third cell type included in the 3D model were monocyte-derived macrophages (MDMs) differentiated from PBMCs, which showed a similar phenotype to human bone marrow-derived macrophages, but could be produced in greater quantities. The Saos-2 cells,
FD HBMSCs and MDMs were introduced into the 3D bone models. Changes in the expression of CD68, CD105 and RANK were found between combinations of the three cell types, as well as those treated with and without Mifamurtide. No significant changes in bone formation or resorption were detected.
In summary, a 3D multicellular bone model of osteosarcoma has been developed that holds the potential to be used to test new drugs and therapies. While further analysis is needed to determine whether the stromal and immune cell interactions replicate those found in the osteosarcoma microenvironment, it has been shown that multiple cell types can be combined in a 3D human bone scaffold, cultured on the CAM and remain viable.

Text
Developing a 3-Dimensional Multicellular Bone Model of Osteosarcoma - Version of Record
Available under License University of Southampton Thesis Licence.
Download (13MB)
Text
Permission to deposit thesis - form_TAN
Restricted to Repository staff only

More information

Published date: April 2022

Identifiers

Local EPrints ID: 475928
URI: http://eprints.soton.ac.uk/id/eprint/475928
PURE UUID: d84a3d8e-a004-4cb2-b8d4-df159b10c3c4
ORCID for Stephen Beers: ORCID iD orcid.org/0000-0002-3765-3342

Catalogue record

Date deposited: 31 Mar 2023 16:35
Last modified: 12 Aug 2024 04:01

Export record

Contributors

Author: Hannah Louise Smith
Thesis advisor: Stephen Beers ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×